23andMe
223 N Mathilda Ave
Sunnyvale
CA
94086
United States
Tel: (800) 239-5230
Website: https://www.23andme.com/
Email: jobs@23andme.com
About 23andMe
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named by Glassdoor as one of The Best Places to Work. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021. More information is available at www.23andMe.com.
Stock Symbol: ME
Stock Exchange: NASDAQ
Discover Your DNA Story With 23andMe!
176 articles with 23andMe
-
23andMe Offers New Genetic Report on Type 2 Diabetes
3/10/2019
Personal genomics company 23andMe offers a new health predisposition report on type 2 diabetes, a condition predicted to affect 40 percent of Americans in their lifetime.
-
Lark Health and 23andMe Collaborate to Integrate Genetic Information in Two New Health Programs
1/8/2019
Lark's clinically validated AI coaching programs provide new ways for 23andMe customers to take action on their genetic information
-
When consumers have their genome tested by services like 23andMe and Ancestry.com, the companies hold the rights to the genetic information, which they often sell to biopharmaceutical companies. Nebula Genomics is taking a different approach.
-
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
-
23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports
10/31/2018
The decision allows 23andMe to report directly to customers, without a prescription, the influence their genetics have on how well they metabolize certain medications
-
19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties
10/19/2018
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry. -
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
-
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
-
In looking at companies that are shaping the future, Time Magazine selected 50 business that are leading the charge. While many tech companies lead the way, there are several pharma and life science companies that are also disrupting the future.
-
Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.
-
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
-
TimiHealth Program Empowering Consumers to Profit from their DNA Data Will Be Listed on LATOKEN Where Trading Starts Aug. 9, Part of a Two Million Timicoin Giveaway
8/8/2018
Timicoin/TimiHealth (www.timicoin.io),the first operating blockchain designed to empower individuals through itsTimiDNA platform to own, control, and monetize their genetic DNA data,will also be the first to actually pay them for it via LATOKEN (www.LATOKEN.COM).
-
Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.
-
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
-
10 Women Biotech CEOs Lead the Charge
6/26/2018
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives. -
Rigel Appoints Dean Schorno as Chief Financial Officer
5/30/2018
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
-
The U.S. Food and Drug Administration (FDA) approved the first-ever direct-to-consumer genetic test for cancer risk.
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
23andMe Granted First FDA Authorization for Direct-to-Consumer Genetic Test on Cancer Risk
3/6/2018
Authorization allows 23andMe to report on BRCA1- and BRCA2-related genetic risk for breast, ovarian and prostate cancer
-
A look at whether big money and big deals will be in store for 2018.